Related Experiment Video
Updated: Nov 7, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
The Three Pillars of COVID-19 Convalescent Plasma Therapy
Massimo Franchini1, Giancarlo Maria Liumbruno1, Giorgio Piacentini2
1Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantova, Italy.
Insights
Convalescent plasma therapy for COVID-19 is being explored. This review analyzes key factors like plasma, disease severity, and patient characteristics to determine treatment effectiveness.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused coronavirus disease 2019 (COVID-19) pandemic.
- COVID-19 remains a significant global public health threat.
- Effective pharmacological treatments for COVID-19 are still lacking, posing therapeutic challenges.
Purpose of the Study:
- To critically analyze the clinical effectiveness of convalescent plasma therapy for COVID-19.
- To examine the three key factors influencing treatment outcomes: convalescent plasma, the disease (COVID-19), and patient characteristics.
Main Methods:
- This study is a narrative review.
- It synthesizes existing knowledge on passive immunotherapy using convalescent plasma.
- The review critically analyzes the interplay between plasma, disease, and patient factors.
Main Results:
- Passive immunotherapy via convalescent plasma has been extensively investigated.
- The effectiveness of this biologic therapy is contingent upon multiple factors.
- A comprehensive understanding of these factors is crucial for optimizing treatment.
Conclusions:
- Convalescent plasma therapy holds potential but requires careful consideration of its components.
- The clinical success of this approach depends on the quality of the plasma, the stage and severity of COVID-19, and individual patient factors.
- Further research and critical analysis are needed to refine this therapeutic strategy.
Abstract:
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly around the world in the last year causing the coronavirus disease 2019 (COVID-19), which still is a severe threat for public health. The therapeutic management of COVID-19 is challenging as, up until now, no specific and efficient pharmacological therapy has been validated. Translating the experience from previous viral epidemics, passive immunotherapy by means of plasma from individuals recovered from COVID-19 has been intensively investigated since the beginning of the pandemic. In this narrative review, we critically analyze the three factors, named "pillars", that play a key role in determining the clinical effectiveness of this biologic therapy: the convalescent plasma, the disease (COVID-19), and the patients.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
